LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research report issued on Monday, April 15th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.51) for the Read this story
